Compelling top-line Phase III trial results for Dermavant's Vtama

Dermavant Sciences, an immuno-dermatology-focused subsidiary of Switzerland-based Roivant Sciences (Nasdaq: ROIV), has disclosed highly compelling Phase III data from the ADORING 2 trial, the first top-line data from Vtama (tapinarof) in atopic dermatitis (AD) of a two-trial series. Roivant’s shares moved up almost 7% to $8.52 on the news.

In ADORING 2 (N=406), Vtama cream met the primary endpoint of the trial and demonstrated highly statistically-significant improvement in the vIGA-AD score of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8 (P<0.0001).

Additionally, Vtama cream demonstrated highly statistically-significant improvement in the proportion of subjects with >75% improvement in EASI75 from baseline at week 8 (P<0.0001), a key secondary endpoint. Subjects 12 years and older receiving Vtama cream also experienced a highly statistically-significant improvement >4-point reduction in Peak Pruritis Numeric Rating Scale (PP-NRS) in itch (P=0.0015), another key secondary endpoint in the study due to its prevalence among AD sufferers.